OPKO Health, Inc. is a diversified biopharmaceutical and diagnostics company headquartered in Miami, Florida. Since its incorporation in 2007, OPKO Health has focused on advancing innovative molecular medicine and improving patient care through its two core business segments. The company has grown both organically and through strategic acquisitions, notably the 2015 acquisition of BioReference Laboratories, and today offers a broad range of products and services spanning diagnostics, pharmaceuticals and biologics.
In its diagnostics segment, OPKO Health operates under the BioReference Laboratories brand, one of the largest full-service specialty laboratories in the United States. This division provides clinical testing services for oncology, women’s health, perinatology and genetic disorders, among other areas. BioReference Laboratories’ offerings include routine blood testing, advanced genomic profiling, non-invasive prenatal screening and hereditary cancer panels. The network of testing facilities and patient service centers supports healthcare providers and patients across all 50 states, Puerto Rico and select international markets.
The pharmaceuticals segment of OPKO Health focuses on the development, manufacturing and commercialization of both proprietary and branded pharmaceutical products. Key offerings include Rayaldee, an FDA-approved therapy for secondary hyperparathyroidism in chronic kidney disease, and VARUBI, an antiemetic for chemotherapy-induced nausea and vomiting. Additional products in the portfolio encompass hemostasis therapies such as NOVOSEVEN RT, as well as a line of generic formulations. The company maintains strategic partnerships and licensing agreements to expand the reach of its pipeline candidates and marketed products in territories throughout North America, Europe and Latin America.
OPKO Health serves patients and healthcare providers in the United States, Puerto Rico, Latin America, Europe and India, leveraging a combination of in-house manufacturing, strategic alliances and commercial infrastructure. Under the leadership of Chairman and Chief Executive Officer Dr. Phillip Frost, a veteran in the life sciences industry, the company continues to advance its integrated approach to diagnostics and therapeutics. Dr. Frost, together with a seasoned management team, is committed to driving innovation in molecular medicine and delivering value to both patients and stakeholders worldwide.
AI Generated. May Contain Errors.
